NO870104L - Farmasoeytisk preparat med vedvarende frigivelse av den aktive komponenten og fremgangsmaate for fremstilling derav. - Google Patents
Farmasoeytisk preparat med vedvarende frigivelse av den aktive komponenten og fremgangsmaate for fremstilling derav. Download PDFInfo
- Publication number
- NO870104L NO870104L NO870104A NO870104A NO870104L NO 870104 L NO870104 L NO 870104L NO 870104 A NO870104 A NO 870104A NO 870104 A NO870104 A NO 870104A NO 870104 L NO870104 L NO 870104L
- Authority
- NO
- Norway
- Prior art keywords
- active component
- sucrose
- pharmaceutical preparation
- tablet
- release
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 17
- 238000000034 method Methods 0.000 title claims description 12
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 17
- 229960001680 ibuprofen Drugs 0.000 claims description 17
- 239000000194 fatty acid Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 150000004665 fatty acids Chemical class 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- XZAGBDSOKNXTDT-UHFFFAOYSA-N Sucrose monopalmitate Chemical compound CCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 XZAGBDSOKNXTDT-UHFFFAOYSA-N 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000012730 sustained-release form Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000013268 sustained release Methods 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 150000003445 sucroses Chemical class 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- -1 sucrose ester Chemical class 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 5
- 238000000576 coating method Methods 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8600050A NL8600050A (nl) | 1986-01-13 | 1986-01-13 | Farmaceutisch preparaat met vertraagde afgifte van het werkzame bestanddeel en werkwijze voor de bereiding er van. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO870104D0 NO870104D0 (no) | 1987-01-12 |
| NO870104L true NO870104L (no) | 1987-07-14 |
Family
ID=19847407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO870104A NO870104L (no) | 1986-01-13 | 1987-01-12 | Farmasoeytisk preparat med vedvarende frigivelse av den aktive komponenten og fremgangsmaate for fremstilling derav. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0230332A1 (fr) |
| JP (1) | JPS62209025A (fr) |
| DK (1) | DK16187A (fr) |
| FI (1) | FI870092A (fr) |
| IL (1) | IL81232A0 (fr) |
| NL (1) | NL8600050A (fr) |
| NO (1) | NO870104L (fr) |
| ZA (1) | ZA87216B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE68346T1 (de) * | 1987-07-22 | 1991-11-15 | Farvalsa Ag | Feuchtigkeitsstabile feste valproinsaeurezubereitung und verfahren zu ihrer herstellung. |
| JPH023609A (ja) * | 1988-06-21 | 1990-01-09 | Fujimoto Seiyaku Kk | 塩酸ニカルジピンを活性成分とする持効性製剤 |
| GR1000466B (el) * | 1989-01-28 | 1992-07-30 | Sandoz Ag | Μεθοδος παρασκευης νεων φαρμακευτικων μορφων κυκλοσπορινης. |
| BE1003009A5 (fr) * | 1989-02-09 | 1991-10-22 | Sandoz Sa | Nouvelles compositions pharmaceutiques a base de cyclosporines. |
| US5268181A (en) * | 1989-04-13 | 1993-12-07 | Upsher-Smith Laboratories, Inc. | Method of using niacin to control nocturnal cholesterol synthesis |
| GB9325445D0 (en) | 1993-12-13 | 1994-02-16 | Cortecs Ltd | Pharmaceutical formulations |
| DE19840152A1 (de) * | 1998-09-03 | 2000-03-09 | Dresden Arzneimittel | Calciumvalproat enthaltende pharmazeutische Zusammensetzungen mit retardierter Wirkstoff-Freisetzung, Verfahren zu deren Herstellung und deren Verwendung |
| WO2000025598A1 (fr) * | 1998-11-03 | 2000-05-11 | Dandy A/S | Esters d'acide gras de saccharose prevus pour augmenter la liberation d'ingredients actifs |
| US20030027786A1 (en) | 2001-06-06 | 2003-02-06 | Karsten Maeder | Lipase inhibiting composition |
| KR20030095600A (ko) * | 2002-06-12 | 2003-12-24 | 환인제약 주식회사 | 펠로디핀을 포함하는 제어방출형 조성물 및 그 제조방법 |
| DK1660047T3 (en) | 2003-08-13 | 2014-03-10 | Biocon Ltd | MICROPARTICALLY FATIC ACID SALT SOLID DOSAGE FORMS FOR THERAPEUTIC AGENTS |
| JP7469550B1 (ja) * | 2022-10-21 | 2024-04-16 | 第一工業製薬株式会社 | 固体組成物及びその製造方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1080265B (de) * | 1958-09-30 | 1960-04-21 | Bayer Ag | Verfahren zur Herstellung von oral anzuwendenden Arzneimittel-zubereitungen mit protrahierter Wirkung aus Wirkstoffen und Schutzstoffen |
| FR2518403B1 (fr) * | 1981-12-22 | 1987-01-02 | Dietlin Francois | Procede de preparation de formes pharmaceutiques presentant une resorption par voie digestive amelioree, et les formes pharmaceutiques ainsi obtenues |
-
1986
- 1986-01-13 NL NL8600050A patent/NL8600050A/nl not_active Application Discontinuation
-
1987
- 1987-01-12 IL IL81232A patent/IL81232A0/xx unknown
- 1987-01-12 NO NO870104A patent/NO870104L/no unknown
- 1987-01-12 FI FI870092A patent/FI870092A/fi not_active IP Right Cessation
- 1987-01-12 EP EP87200031A patent/EP0230332A1/fr not_active Withdrawn
- 1987-01-13 JP JP62007403A patent/JPS62209025A/ja active Pending
- 1987-01-13 ZA ZA87216A patent/ZA87216B/xx unknown
- 1987-01-13 DK DK016187A patent/DK16187A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO870104D0 (no) | 1987-01-12 |
| EP0230332A1 (fr) | 1987-07-29 |
| JPS62209025A (ja) | 1987-09-14 |
| IL81232A0 (en) | 1987-08-31 |
| FI870092A0 (fi) | 1987-01-12 |
| FI870092A (fi) | 1987-07-14 |
| DK16187A (da) | 1987-07-14 |
| NL8600050A (nl) | 1987-08-03 |
| DK16187D0 (da) | 1987-01-13 |
| ZA87216B (en) | 1987-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0320051B1 (fr) | Combinaison de carbidopa-lévodopa à libération contrôlée | |
| US5631296A (en) | Drugs containing S(+)-ibuprofen | |
| EP0253490B1 (fr) | Association carbidopa-levodopa à libération contrôlée | |
| CA2298659C (fr) | Antalgique d'action rapide | |
| US5741519A (en) | The production of active substance compositions in the form of a solid solution of the active substance in a polymer matrix, and active substance compositions produced by this process | |
| US4900755A (en) | Controlled release combination of carbidopa/levodopa | |
| CA2523158A1 (fr) | Comprime a action retardee et a geometrie de noyau definie | |
| NO870104L (no) | Farmasoeytisk preparat med vedvarende frigivelse av den aktive komponenten og fremgangsmaate for fremstilling derav. | |
| AU2002238848B2 (en) | Use of a spray-dried powder comprising a sugar alcohol | |
| US4983400A (en) | Controlled release combination of carbidopa/levodopa | |
| US5164193A (en) | Sustained-release tablet | |
| JP3382940B2 (ja) | 中枢ドパミン欠乏状態を治療するための経口投与可能な医薬製剤 | |
| EP0014514A2 (fr) | Procédé de fabrication de comprimés | |
| NO318890B1 (no) | Oksykodonformuleringer med kontrollert frigivelse og anvendelse av slike for fremstilling av smertelindrende medikamenter | |
| EP1185253B1 (fr) | Forme galenique orale servant a administrer une combinaison fixe de tramadol et de diclofenac | |
| NO173081B (no) | Fremgangsmaate for fremstilling av et retard-preparat av ibuprofen | |
| US5624960A (en) | Orally administrable drugs for the treatment of central dopamine deficiency conditions | |
| CA2416771C (fr) | Acide 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetique pour le traitement de troubles relies au cox-2 | |
| EP0999828B1 (fr) | Procede de production de preparations de principe actif avec liberation controlee a partir d'une matrice | |
| NO171887B (no) | Fremgangsmaate for fremstilling av en fast administreringsform for oral anvendelse basert paa nifedipin med kontrollert frigivelse av det aktive stoffet | |
| AU2017279760A1 (en) | Drug substance preparations, pharmaceutical compositions and dosage forms comprising S-(+)-flurbiprofen | |
| JP4020983B2 (ja) | 持続性製剤およびその製法 | |
| JPH05306225A (ja) | 持続性製剤 | |
| CN106822019A (zh) | 一种阿司匹林肠溶片及其制备方法 | |
| EP1325740B1 (fr) | Granules stables contenant de la S-adénosylméthionine et procédé de préparation |